GlassScriptPhysician profile
Steven S Sands
NPI 1376728907
$136,936.91
in general payments reported to CMS, 2019-2025
32 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Orthopaedic Trauma provider received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $22K · 2021: $13K · 2022: $26K · 2023: $6,063 · 2024: $2,105 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,200 · Food and Beverage: $1,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,200.00 |
| Food and Beverage | $1,282.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $128,412.16 | 2019-2024 | Allofiber, Augment Injectable, Ignite |
| Bioventus LLC | $5,538.72 | 2019-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Smith+Nephew, INC. | $907.81 | 2019-2023 | Evos, Trigen Intertan, Maverick |
| Acera Surgical, INC. | $316.23 | 2022-2025 | Restrata Wound Matrix |
| Si-Bone, INC. | $178.77 | 2019-2022 | |
| Depuy Synthes Sales INC. | $177.67 | 2019-2023 | Na |
| Orthofix Medical, INC. | $163.13 | 2019-2024 | Physio-Stim, Cervical-Stim, Spinal-Stim |
| Novastep INC. | $148.12 | 2022 | |
| Organogenesis INC. | $141.94 | 2021-2022 | |
| Maxx Health INC | $139.00 | 2025 | Summa Ortho Distal Radius 2, Summa Ortho Clavicle |
| Skeletal Dynamics INC | $134.87 | 2024 | Implate, Align, Geminus |
| Dynasplint Systems INC. | $96.00 | 2019-2020 | |
| Polynovo North America LLC | $63.76 | 2023-2024 | Novosorb Btm |
| Pacira Therapeutics, INC. | $55.81 | 2019-2021 | |
| Ethicon US, LLC | $53.97 | 2019-2025 | Stratafix, Vicryl |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $49.66 | 2021-2022 | |
| Pylant Medical | $43.20 | 2023-2024 | |
| Medtronic, INC. | $43.11 | 2025 | Inceptiv |
| Innovation Technologies INC | $42.36 | 2024-2025 | Irrisept |
| Biocomposites INC | $36.69 | 2024 | |
| Ferring Pharmaceuticals INC. | $34.99 | 2019 | |
| Pfizer INC. | $24.92 | 2019 | |
| Kci USA, INC. | $23.30 | 2019 | |
| Zimmer Biomet Holdings, INC. | $19.75 | 2019 | |
| Medacta USA, INC. | $19.22 | 2024 | |
| Nuvasive Specialized Orthopedics, INC. | $17.78 | 2019 | |
| Acumed LLC | $16.00 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.24 | 2023 | Zilretta, Iovera, Exparel |
| Abbott Laboratories | $11.41 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.32 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,905,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sands listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.